Chimeric Antigen Receptor T Cell Immunotherapy for Autoimmune Rheumatic Disorders: Where Are We Now?

Chimeric antigen receptor (CAR) T cell immunotherapy has changed the landscape of B cell hematological malignancies’ management, while it has recently shown promising results in the treatment of refractory autoimmune rheumatic disorders (ARDs). Targeting B cell antigens such as CD19 and BCMA, CAR-T...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Panagiota Anyfanti, Paschalis Evangelidis, Nikolaos Kotsiou, Anna Papakonstantinou, Ioannis Eftychidis, Ioanna Sakellari, Theodoros Dimitroulas, Eleni Gavriilaki
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI AG 2025-08-01
Colecção:Cells
Assuntos:
autoimmune rheumatic disorders
BCMA
CAR-T cell therapy
CD19
immunotherapy
systemic lupus erythematosus
Acesso em linha:https://www.mdpi.com/2073-4409/14/16/1242
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados